arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

download Export Data

PharmaCyte Biotech, Inc.

PMCB

$0.59 ▲ +0.01 (+1.05%) at close

17 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

PharmaCyte Biotech, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.9M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -16.3% ↘

FCF / Share $-0.62 ↘

Trailing P/E —

Price / Book 0.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

17-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-19.42M

↓ -163.4% —

FCF / Share Free cash flow per share

$-0.62

↓ -51.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗	FY 2018 Apr 30, 2018 10-K ↗	FY 2017 Apr 30, 2017 10-K ↗	FY 2016 Apr 30, 2016 10-K ↗	FY 2015 Apr 30, 2015 10-K ↗	FY 2014 Apr 30, 2014 10-K ↗	FY 2013 Apr 30, 2013 10-K ↗	FY 2012 Apr 30, 2012 10-K ↗	FY 2011 Apr 30, 2011 10-K ↗	FY 2010 Apr 30, 2010 10-K ↗
Revenue Growth YoY (%)	—	—	—	—	—	—	—	—	—	—	—	—	N/M	-81.7% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1122%)	-47.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-690%)	—	—
EPS Growth YoY (%)	N/M	N/M	-718.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	18.5% Good Good Year-over-year change in earnings per share Optimal: > 10%	89.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	100.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	N/M	9085.0% Excellent ↑ Excellent Improving Year-over-year change in net income	N/M	-1.8% Weak ↑ Weak Improving Year-over-year change in net income	-19.4% Weak ↓ Weak Declining Year-over-year change in net income	7.2% Fair ↑ Fair Improving Year-over-year change in net income	5.9% Fair ↑ Fair Improving Year-over-year change in net income	40.4% Excellent ↑ Excellent Improving Year-over-year change in net income	-53.7% Weak ↓ Weak Declining Year-over-year change in net income	26.7% Excellent ↑ Excellent Improving Year-over-year change in net income	44.1% Excellent ↑ Excellent Improving Year-over-year change in net income	60.2% Excellent ↑ Excellent Improving Year-over-year change in net income	-1605.4% Weak ↓ Weak Declining Year-over-year change in net income	15.9% Good Good Year-over-year change in net income	-35.9% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-51.4% Weak ↓ Weak Declining Year-over-year change in free cash flow	-81.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	-15.4% Weak ↓ Weak Declining Year-over-year change in free cash flow	26.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	88.5% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	11.1% Fair ↑ Fair Improving Year-over-year change in free cash flow	-98799.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	50.1% Excellent Excellent Year-over-year change in free cash flow	-32.7% Weak Weak Year-over-year change in free cash flow	—	—	—	—	-28.0% Weak Weak Year-over-year change in free cash flow	-7.6% Weak Weak Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗	FY 2018 Apr 30, 2018 10-K ↗	FY 2017 Apr 30, 2017 10-K ↗	FY 2016 Apr 30, 2016 10-K ↗	FY 2015 Apr 30, 2015 10-K ↗	FY 2014 Apr 30, 2014 10-K ↗	FY 2013 Apr 30, 2013 10-K ↗	FY 2012 Apr 30, 2012 10-K ↗	FY 2011 Apr 30, 2011 10-K ↗	FY 2010 Apr 30, 2010 10-K ↗
FCF Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-389.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-178.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.27x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.10x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-6.45x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.61x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	0.24x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.14x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.16x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗	FY 2018 Apr 30, 2018 10-K ↗	FY 2017 Apr 30, 2017 10-K ↗	FY 2016 Apr 30, 2016 10-K ↗	FY 2015 Apr 30, 2015 10-K ↗	FY 2014 Apr 30, 2014 10-K ↗	FY 2013 Apr 30, 2013 10-K ↗	FY 2012 Apr 30, 2012 10-K ↗	FY 2011 Apr 30, 2011 10-K ↗	FY 2010 Apr 30, 2010 10-K ↗
Return on Invested Capital (%)	-16.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-24.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-3.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-42.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-59.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-64.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-95.6% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-43.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-73.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-182.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-167.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	88.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	67.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-14.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-7.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-14.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-4.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-48.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-62.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-70.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-108.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-51.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-84.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-172.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-203.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-58.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-93.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-58.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-489%)	59.1% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+294%)	1.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-92%)	-5.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-140%)	-4.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-131%)	-53.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-454%)	-75.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-601%)	-80.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-638%)	-118.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-889%)	-54.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-466%)	-93.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-720%)	-182.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1319%)	—	106.4% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+610%)	83.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+455%)	51.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+241%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗	FY 2018 Apr 30, 2018 10-K ↗	FY 2017 Apr 30, 2017 10-K ↗	FY 2016 Apr 30, 2016 10-K ↗	FY 2015 Apr 30, 2015 10-K ↗	FY 2014 Apr 30, 2014 10-K ↗	FY 2013 Apr 30, 2013 10-K ↗	FY 2012 Apr 30, 2012 10-K ↗	FY 2011 Apr 30, 2011 10-K ↗	FY 2010 Apr 30, 2010 10-K ↗
Interest Coverage (x)	—	—	—	—	-8628.71x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1189.42x Weak Weak Operating income divided by interest expense Optimal: > 5x	-8446.79x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	-2886.38x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-5099.19x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-2773.49x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-950.72x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-14.95x Weak Weak Operating income divided by interest expense Optimal: > 5x	-8.47x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-18.60M	$-15.17M	$-50.18M	$-68.04M	$-85.40M	—	—	—	—	—	—	—	—	$-199.30K	$-15.72K	$-57.20K	$-716.00

📊 What does each share earn? 6 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗	FY 2018 Apr 30, 2018 10-K ↗	FY 2017 Apr 30, 2017 10-K ↗	FY 2016 Apr 30, 2016 10-K ↗	FY 2015 Apr 30, 2015 10-K ↗	FY 2014 Apr 30, 2014 10-K ↗	FY 2013 Apr 30, 2013 10-K ↗	FY 2012 Apr 30, 2012 10-K ↗	FY 2011 Apr 30, 2011 10-K ↗	FY 2010 Apr 30, 2010 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	—
Basic EPS, GAAP (USD)	$-2.77	$3.19	$-1.80	$-0.22	$-0.27	$-2.45	—	—	—	—	—	—	—	$0.00	$-0.01	$0.00	—
Free Cash Flow per Share (USD)	$-0.62	$-0.41	$-0.22	$-0.19	$-0.27	$-2.30	$-2.59	$-0.00	$-0.01	$-0.00	—	—	—	$-0.00	$-0.00	$-0.00	—
Book Value per Share (USD)	$3.10	$7.64	$3.44	$4.33	$4.34	$4.20	$4.66	$0.00	$0.01	$0.01	$0.01	$0.01	$0.01	$-0.00	$-0.01	$-0.01	—
Tangible Book Value per Share (USD)	$3.10	$7.41	$3.25	$4.12	$4.17	$4.20	$4.66	$0.00	$0.01	$0.01	$0.01	$0.01	$0.01	$-0.00	$-0.01	$-0.01	—
Basic Weighted Avg Shares (shares)	8.38M	7.33M	9.58M	19.49M	15.52M	1.45M	903,812	1.10B	968.64M	845.31M	752.40M	704.33M	583.22M	440.95M	374.76M	350.34M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗	FY 2018 Apr 30, 2018 10-K ↗	FY 2017 Apr 30, 2017 10-K ↗	FY 2016 Apr 30, 2016 10-K ↗	FY 2015 Apr 30, 2015 10-K ↗	FY 2014 Apr 30, 2014 10-K ↗	FY 2013 Apr 30, 2013 10-K ↗	FY 2012 Apr 30, 2012 10-K ↗	FY 2011 Apr 30, 2011 10-K ↗	FY 2010 Apr 30, 2010 10-K ↗
Working Capital (USD)	$36.59M	$19.46M	$43.02M	$67.56M	$84.79M	$1.55M	$6.25K	$-89.45K	$639.70K	$2.96M	$1.39M	$806.58K	$3.81M	$-1.95M	$-2.73M	$-3.28M	—
Total Equity (USD)	$33.29M	$51.89M	$27.65M	$72.69M	$89.92M	$6.68M	$5.09M	$5.04M	$5.77M	$8.09M	$6.52M	$5.94M	$8.94M	$-1.50M	$-2.28M	$-2.73M	$-2.45M

📋 What is driving earnings? 4 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗	FY 2020 Apr 30, 2020 10-K ↗	FY 2019 Apr 30, 2019 10-K ↗	FY 2018 Apr 30, 2018 10-K ↗	FY 2017 Apr 30, 2017 10-K ↗	FY 2016 Apr 30, 2016 10-K ↗	FY 2015 Apr 30, 2015 10-K ↗	FY 2014 Apr 30, 2014 10-K ↗	FY 2013 Apr 30, 2013 10-K ↗	FY 2012 Apr 30, 2012 10-K ↗	FY 2011 Apr 30, 2011 10-K ↗	FY 2010 Apr 30, 2010 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$12.16K	$66.56K	$126.00K	—
Depreciation Expense (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	$0.00	$24.66K	—	—
Net Income, GAAP (USD)	$-19.42M	$30.66M	$333.76K	$-4.32M	$-4.24M	$-3.55M	$-3.83M	$-4.07M	$-6.83M	$-4.44M	$-6.06M	$-10.85M	$-27.25M	$-1.60M	$-1.90M	$-1.40M	—
Operating Cash Flow (USD)	$-5.15M	$-2.98M	$-2.15M	$-3.79M	$-4.12M	$-3.33M	$-2.34M	$-2.88M	$-5.08M	$-3.34M	—	—	—	$-390.43K	$-259.29K	$-225.23K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 64 quarters

PharmaCyte Biotech, Inc.

Analytical Summary

17-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PMCB with peers